Abstract 658: CBS9106 is a novel low toxic reversible oral CRM1 inhibitor with CRM1 degrading activity von Sakakibara, Keiichi, Saito, Naoya, Sato, Takuji, Suzuki, Atsushi, Hasegawa, Yoko, Friedman, Jonathan M., Suganuma, Masashi, Kufe, Donald W., VanHoff, Daniel D., Iwami, Tadahiko, Kawabe, Takumi

Volltext

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial von BURRIS, H. A, MOORE, M. J, NELSON, R, DORR, F. A, STEPHENS, C. D, VON HOFF, D. D, ANDERSEN, J, GREEN, M. R, ROTHENBERG, M. L, MODIANO, M. R, CRIPPS, M. C, PORTENOY, R. K, STORNIOLO, A. M, TARASSOFF, P

Volltext

Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity von van Hoff, Jack, Grier, Holcombe E., Douglass, Edwin C., Green, Daniel M.

Volltext